INTRODUCTION: We aimed to investigate whether patients on active surveillance (AS) had worse outcomes than patients who received immediate treatment with radiotherapy and whether a Gleason grade progression on repeat biopsy influenced outcome. METHODS: From our institutional database, we identified 2001 patients treated between 2005 and 2019 with primary external beam radiation therapy or brachytherapy. Biochemical recurrence (BCR) was analyzed in relation to clinical factors such as a Gleason grade progression or having multiple biopsies vs. only one biopsy. Patients on AS were identified as those who had undergone ≥2 biopsies. We used log-rank tests for univariate analysis (UVA) and Cox regression analysis for multivariable analysis (MVA). RESULTS: Of 2001 patients, 374 (19%) patients had ≥2 biopsies before treatment, of which 48% presented with a Gleason grade progression of mostly to Gleason 3+4 (36%); 32% had a cancer volume increase on biopsy and 16% had no significant change on biopsy. For patients with ≥2 biopsies, median time from first biopsy to treatment was 22.0 months (interquartile range [IQR] 14.7-36.1). By UVA, patients with Gleason grade progression (n=105) had a worse BCR-free rate (p=0.02) than patients who had no grade progression on repeat biopsy or only one biopsy. On MVA, this effect was lost. Having ≥2 biopsies was not a significant negative prognostic factor on UVA (p=0.2) or MVA. CONCLUSIONS: In our experience, radiotherapy after a period of AS, even with Gleason grade progression, did not lead to worse outcomes compared to patients who had radiotherapy after only one biopsy.
INTRODUCTION: We aimed to investigate whether patients on active surveillance (AS) had worse outcomes than patients who received immediate treatment with radiotherapy and whether a Gleason grade progression on repeat biopsy influenced outcome. METHODS: From our institutional database, we identified 2001 patients treated between 2005 and 2019 with primary external beam radiation therapy or brachytherapy. Biochemical recurrence (BCR) was analyzed in relation to clinical factors such as a Gleason grade progression or having multiple biopsies vs. only one biopsy. Patients on AS were identified as those who had undergone ≥2 biopsies. We used log-rank tests for univariate analysis (UVA) and Cox regression analysis for multivariable analysis (MVA). RESULTS: Of 2001 patients, 374 (19%) patients had ≥2 biopsies before treatment, of which 48% presented with a Gleason grade progression of mostly to Gleason 3+4 (36%); 32% had a cancer volume increase on biopsy and 16% had no significant change on biopsy. For patients with ≥2 biopsies, median time from first biopsy to treatment was 22.0 months (interquartile range [IQR] 14.7-36.1). By UVA, patients with Gleason grade progression (n=105) had a worse BCR-free rate (p=0.02) than patients who had no grade progression on repeat biopsy or only one biopsy. On MVA, this effect was lost. Having ≥2 biopsies was not a significant negative prognostic factor on UVA (p=0.2) or MVA. CONCLUSIONS: In our experience, radiotherapy after a period of AS, even with Gleason grade progression, did not lead to worse outcomes compared to patients who had radiotherapy after only one biopsy.
Authors: Chris H Bangma; Riccardo Valdagni; Peter R Carroll; Hein van Poppel; Laurence Klotz; Jonas Hugosson Journal: Eur Urol Date: 2014-11-27 Impact factor: 20.096
Authors: Brandon A Mahal; Santino Butler; Idalid Franco; Daniel E Spratt; Timothy R Rebbeck; Anthony V D'Amico; Paul L Nguyen Journal: JAMA Date: 2019-02-19 Impact factor: 56.272
Authors: Jeremy B Shelton; Thomas A Paivanas; Phil Buffington; Stephen R Ruyle; Edward S Cohen; Richard Natale; Bryan Mehlhaff; Ronald Suh; Timothy J Bradford; Alec S Koo; Lorna Kwan; Neal Shore Journal: Urology Date: 2019-04-25 Impact factor: 2.649
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Ashwin S Balakrishnan; Janet E Cowan; Matthew R Cooperberg; Katsuto Shinohara; Hao G Nguyen; Peter R Carroll Journal: J Urol Date: 2019-08-08 Impact factor: 7.450
Authors: Michael J Whalen; Jamie S Pak; Danny Lascano; David Ahlborn; Justin T Matulay; James M McKiernan; Mitchell C Benson; Sven Wenske Journal: Clin Genitourin Cancer Date: 2017-10-16 Impact factor: 2.872
Authors: Lisa F Newcomb; Ian M Thompson; Hilary D Boyer; James D Brooks; Peter R Carroll; Matthew R Cooperberg; Atreya Dash; William J Ellis; Ladan Fazli; Ziding Feng; Martin E Gleave; Priya Kunju; Raymond S Lance; Jesse K McKenney; Maxwell V Meng; Marlo M Nicolas; Martin G Sanda; Jeffry Simko; Alan So; Maria S Tretiakova; Dean A Troyer; Lawrence D True; Funda Vakar-Lopez; Jeff Virgin; Andrew A Wagner; John T Wei; Yingye Zheng; Peter S Nelson; Daniel W Lin Journal: J Urol Date: 2015-08-29 Impact factor: 7.450
Authors: Alejandro Berlin; Ardalan E Ahmad; Melvin L K Chua; Fabio Y Moraes; Haiyan Jiang; Maria Komisarenko; Narhari Trimilshina; Hamid Raziee; Ali Hosni; Jure Murgic; Peter Chung; Robert G Bristow; Antonio Finelli Journal: Int J Radiat Oncol Biol Phys Date: 2017-11-01 Impact factor: 7.038